We studied the effects of fluvoxamine and amitriptyline on epicardial activation delay of premature excitations, the effective refractory period, and the incidence of ventricular arrhythmias by programmed electrical ventricular stimulation in the canine heart after myocardial infarction. Additionally, we investigated whether the inhibition of norepinephrine reuptake by amitriptyline contributes to epicardial activation delay or arrhythmias by combination with propranolol pretreatment. Amitriptyline, at a dose of 3 mg/kg, significantly prolonged epicardial activation delay of premature excitations in the infarcted zone in a frequency-dependent manner (n = 10). Amitriptyline also prolonged epicardial activation delay of premature excitations in the normal zone (n = 10). The effective refractory period in the infarcted zone was significantly prolonged by amitriptyline at a dose of 3 mg/kg (n = 8). Amitriptyline increased the incidence of ventricular arrhythmias induced by programmed electrical ventricular stimulation (n = 8). Propranolol did not affect the epicardial activation delay caused by amitriptyline or the incidence of ventricular arrhythmias induced by programmed electrical ventricular stimulation (n = 6). Fluvoxamine, on the other hand, had no significant effect on epicardial activation delay of premature excitations (n = 10) or the effective refractory period (n = 8) in both the infarcted and normal zones. Fluvoxamine did not increase the incidence of ventricular arrhythmias induced by programmed electrical ventricular stimulation (n = 8). From the present results, fluvoxamine seems to have lower cardiac toxicity than amitriptyline. Moreover, the electrophysiological effects of amitriptyline in this model may be due to a direct cardiac depressive action, but not to the inhibition of norepinephrine reuptake.
Introduction
Amitriptyline is among the most frequently used drugs in the treatment of psychological depression. However, the recent widespread use of amitriptyline has revealed its arrhythmogenic effects, especially in patients with preexisting cardiac disease (Marshall and Forker 1982) . The in vivo mechanisms of tricyclic antidepressant (TCA)-induced cardiac arrhythmias are imperfectly understood, but some of these actions may be due to their sodium channel blocking effects (Starmer et al. 1992; Roose and Glassman 1994) . We have shown that amitriptyline, at therapeutic doses, markedly slows intraventricular conduction, especially in infarcted myocardium, and increases the incidence of ventricular arrhythmias induced by programmed stimulation in the dog heart after myocardial infarction (Nishimoto et al. 1990) .
Several TCAs are known to inhibit the neuronal uptake of amines in the heart (Hertting et al. 1961; Carlsson and Waldeck 1965; Iversen 1965) . It has been reported that catecholamines affect the conduction velocity in a complex manner in guinea pig ventricular papillary muscles (Hisatome and Arita 1995) , and thus inhibition of norepinephrine-uptake by amitriptyline may also affect intraventricular conduction.
In recent years, selective serotonin reuptake inhibitors (SSRIs) have been introduced because of their lower incidence of side effects and high potency in depressive patients. Fluvoxamine is an SSRI which is now in the spotlight for its low incidence of cardiac side effects (Roos 1983; Laird et al. 1993) . Fluvoxamine is structurally quite different from the tricyclic and tetracyclic antidepressants. Its pharmacology and clinical efficacy have been reviewed by Wilde et al. (1993) . However, the cardiovascular effects of fluvoxamine in patients with severe cardiac disease are open to question (Glassman and Preud'homme 1993) .
The present study was undertaken to examine the comparative effects of amitriptyline (a TCA) and fluvoxamine (an SSRI) on epicardial activation delay (which may reflect intraventricular conduction), the effective refractory period (ERP), and the incidence of arrhythmias induced by programmed electrical ventricular stimulation (PES) in the dog heart after myocardial infarction. In addition, we investigated whether the inhibition of norepinephrine reuptake by amitriptyline contributes to epicardial activation delay or arrhythmias by combination with propranolol pretreatment.
Methods
Animal preparation. Mongrel dogs (n = 21) weighing between 6.0 and 15.0kg were anaesthetized with sodium pentobarbital, 30 mg/kg i.v. Each animal was intubated and ventilated with room air by a positive-pressure respirator. Left thoracotomy was performed in the fourth intercostal space, and the heart was exposed. After the pericardium was opened, the left anterior descending coronary artery (LAD) was occluded according to the method of Harris (1950) and then several branches of the LAD were also ligated. The chest was closed immediately after complete occlusion of the coronary artery, and routine postoperative care was performed, including prophylactic antibiotic therapy (i.e., administration of cefazolin i.m. daily) during postinfarction convalescence.
Measurement of epicardial activation delay of premature excitations.
The effects of the drugs were examined in 16 animals. Seven days after LAD ligation, each animal was anaesthetized with sodium pentobarbital, 30 mg/kg i.v. Ventilation was performed as described above. Body temperature was maintained at 36-37 °C with a heating pad. Left thoracotomy was performed, and the pericardium was opened. After the heart was cradled on the pericardium, a bipolar stimulating electrode was sutured to the left atrial appendage for atrial pacing, and several bipolar electrodes were sutured to the left ventricular surface of the infarcted zone to record the epicardial activation delay. One stimulating electrode was sutured to the left ventricle to measure the ERP in the infarcted zone. Two other bipolar electrodes were sutured to the right ventricle: one to record the epicardial activation delay in the normal ventricular myocardium and the other to produce a premature ventricular excitation by electrical stimulation of the right ventricle. The distances from the stimulus site to the recording sites in the normal and infarcted zones were almost identical. Atrial pacing (S1) was performed at a cycle length between 270 and 350 ms throughout the electrophysiological study. Premature stimulation ($2) of the right ventricle was performed with a 5-ms rectangular pulse with a stimulus strength of two times the diastolic threshold. In order to study the effects of drugs on epicardial activation delay, we measured the time delay of premature ventricular excitations in both normal and infarcted zones of the ventricle. The time interval, ranging from the artifact of the premature stimulation to the most delayed measurable wave, was measured on the epicardial bipolar ECGs, and this value was taken as an estimate of the epicardial activation delay. The coupling interval of ventricular stimulation was varied between 300 and 100 ms. Lead II of the ECG and epicardial bipolar ECG tracings were recorded on a multichannel thermal recorder (WS-682G; Nihon Kohden, Tokyo, Japan) at a paper speed of 100 mm/s.
Measurement of ERP.
In 8 animals, the ERP was measured during atrial pacing at a cycle length between 270 and 350 ms. To measure the ERP, premature stimuli with a strength of two times the threshold were applied to the normal and infarcted zones at progressively shorter coupling intervals. The ERP was defined as the longest S1-$2 interval that failed to produce a propagated ventricular response.
Programmed electrical ventricular stimulation (PES)
. PES was performed during atrial pacing at a cycle length between 270 and 350 ms in 14 animals and was applied to the right ventricle using an electrical stimulator (SEN-7103; Nihon Kohden, Tokyo, Japan). Before drug administration, triple ventricular extra stimuli were introduced during atrial pacing at $2-$3-$4 coupling intervals, beginning at 200-ms intervals and decreasing in 10-ms steps until ventricular refractoriness, ventricular premature beats, or ventricular tachycardia occurred. When these changes in response to PES were noted, the coupling intervals were increased by 30 ms. Extra stimuli with the increased coupling intervals did not cause any ventricular arrhythmias before drug administration. After drug administration, extra stimuli with the same coupling intervals were introduced and the incidence of ventricular arrhythmias was examined. A ventricular premature beat (VPB) was defined as four or fewer successive ventricular beats. Ventricular tachycardia (VT) was defined as five or more polymorphic successive beats that failed to terminate spontaneously.
(1) Protocol 1 (n = 15) Comparison of fluvoxamine and amitriptyline on epicardial activation delay of premature excitations (n = 10), ERP (n = 8), the incidence of arrhythmias induced by PES (n = 8), and ECG parameters (n = 15) . After control measurements were obtained, antidepressants were administered in cumulative doses of 0.5, 1, and 3 mg/kg i.v. at 10-min intervals. Postdrug values were measured 5 min after drug administration. Two hours after the first drug was injected, the observed epicardial activation delay, ERP, ECG (RR, PQ, QRS, and QT intervals), and arterial blood pressure returned to baseline values. Then, the second drug was injected. The following drugs were used: amitriptyline hydrochloride (Tryptanol, 1% solution; Merck-Banyu, Tokyo, Japan) and fluvoxamine maleate (Solvay-Meiji Yakuhin K.K., Tokyo, Japan). The doses of the drugs were selected according to the recommended human psychiatric doses.
(2) Protocol 2 (n = 6) Effects of amitriptyline in combination with propranolol pretreatment on heart rate (HR), epicardiaI activation delay of premature excitations, and the incidence of arrhythmias induced by PES. After control measurements were obtained, propranolol was administered at a dose of 0.2 mg/kg i.v. Postdrug values measured 5 rain after administration. After 10 min, amitriptyline was injected to cumulative doses of 0.5, 1, and 3 mg/kg i.v. at 10-rain intervals. Postdrug values were also measured 5 rain after administration. The following drugs were used: amitriptyline hydroehloride and propranolol hydrochloride (Inderal, 0.1% solution; ZENECA Yakuhin K.K., Osaka, Japan). The dose of propranolol was selected according to the recommended clinical dose.
Determination of myocardial infraction size. Infarct size was measured in 7 animals. At the end of the experiment, cardiac arrest was induced by injection of a pentobarbital overdose. The heart was rapidly removed and sectioned in transverse rings of 1.0-cm thickness from apex to base. The tissue slices were rinsed in cold isotonic 
Results

Size of the infarcted area
The size of the infarcted area induced by the experimental procedure was 32.6 _+ 2.5% of the total ventricular area (range 24.8 -38.6%, n = 7).
Protocol 1
Effects of antidepressants on the epicardial activation delay of premature excitations
Seven days after LAD ligation, fractionated potentials were observed in the infarcted zone. The delayed activation was further delayed by premature ventricular stimulation. A typical example of the effect of amitriptyline on the activation delay of premature excitations in the infarcted zone is shown in Fig. 1 . Administration of amitriptyline prolonged the activation delay of premature excitations in a dose-dependent manner in the infarcted zone (white arrows). Amitriptyline also prolonged the epicardial activation delay of premature excitations in the normal zone ( Fig. 1; NZeg, values not shown). Figure 2 shows the percentage changes from control values in the epicardial activation delay of premature excitations in the presence of amitriptyline. Amitriptyline, at a dose of 3 mg/kg (black column), prolonged the epicardial activation delay of premature excitations in a frequency-dependent manner in the infarcted zone. These effects were dose-dependent. Amitriptyline, at a dose of 3 mg/kg, also prolonged the epicardial activation delay of premature excitations in the normal zone, although to a lesser extent than in the infarcted zone. Figure 3 shows that fluvoxamine had no significant effect on the epicardial activation delay of premature excitations in either the infarcted or normal zones.
saline and then incubated in a phosphate-buffered solution of triphenyltetrazolium at 38 °C for 20 min. This provoked a bright red coloration in the presence of dehydrogenase enzymes in the noninfarcted myocardium, whereas infarcted regions remained unstained. The infarcted and noninfarcted areas were traced on acetate sheets. Drawings of the rings of myocardium were then retraced on graph paper and the total ventricular and infarcted areas were determined (Nishimoto et al. 1990 ).
Effects of antidepressants on the ERP
Results of the effects of antidepressants on the ERP are shown in Table 1 . Amitriptyline, at a dose of 3 mg/kg, significantly prolonged the ERP in the infarcted zone.
Fluvoxamine, on the other hand, did not prolong the ERP in either the infarcted or normal zones.
Statistical analysis. All data are expressed as mean _+ SEM. Comparison between control and drug values of the epicardial activation delay of premature excitations (n = 16) and ECG intervals (n = 15) was performed by one-way analysis of variance followed by Dunnett's test. Comparison of the ERP was performed by the paired Student's t-test (n = 8). Fisher's exact test was used to compare the incidence of ventricular arrhythmias induced by PES (n= 14). The criterion for statistical significance was P < 0.05. Figure 4 shows the effect of amitriptyline at a dose of 3 mg/kg. In control experiments, the triple ventricular stimulations did not induce ventricular arrhythmias. Administration of amitriptyline, at a dose of 3 mg/kg, Coupling interval (ms) caused ventricular tachycardia. Figure 5 shows the effect of fluvoxamine at a dose of 3 mg/kg. Fluvoxamine did not cause ventricular arrhythmias in response to PES. Table 2 summarizes the results of PES experiments. Amitriptyline, at a dose of 3 mg/kg, significantly increased the incidence of ventricular arrhythmias induced by PES. Fluvoxamine, on the other hand, did not affect the incidence of arrhythmias. 
Effects of antidepressants on the incidence of ventricular arrhythmias induced by PES
Effects of antidepressants on ECG
The results are summarized in Fig. 6 . Amitriptyline, at doses of 1 and 3 mg/kg, significantly increased HR, and at a dose of 3 mg/kg, prolonged the PQ, QRS, and corrected QT (QTc) intervals. Fluvoxamine had no significant effect on ECG parameters. Coupling interval (ms) 
Effects of amitriptyline in combination with propranoloI pretreatment
Propranolol did not significantly decrease the systolic or mean blood pressure (data not shown). Propanolol was shown to cause a sharp decrease in HR, and administration of amitriptyline failed to increase HR (data not shown). Propranolol showed no significant effect on epicardial activation delay in either the infarcted or normal zones (Fig. 7) . Amitriptyline, at a dose of 3 mg/kg, prolonged epicardial activation delay of premature excitations in the infarcted zone in a frequency-dependent manner (Fig. 7) . The effect of amitriptyline in the normal zone was also significant only at the highest dose (Fig. 7) . Propranolol was not associated with any ventricular arrhythmias by PES, while amitriptyline, at a dose of 3 mg/kg, significantly increased the incidence of ventricular arrhythmias induced by PES (Table 3) .
Discussion
In the present study, we have demonstrated the different electrophysiological effects of fluvoxamine and amitriptyline in the canine heart after myocardial infarction. In addition, we investigated whether the inhibition of norepinephrine reuptake by amitriptyline contributes to epicardial activation delay or arrhythmias by combination with propranolol pretreatment. We employed a canine, 7-day post-myocardial infarction model which discriminates between the TCA and other antidepressants in terms of cardiotoxicity (Nishimoto et al. 1990 ). The electrophysiological effects of amitriptyline in this model were previously described in detail (Nishimoto et al. 1990; Hashimoto et al. 1990 ). These reports showed that amitriptyline prolonged Nishimoto et al. 1990; Hashimoto et al. 1990 ).
The results of the present study with respect to amitriptyline in protocol 1 support these earlier results.
The epicardial activation delay observed in the present study probably represents the time for propagation of electrical activation from the stimulating site to some point in the recording sites in the normal and infarcted zones. Amitriptyline changed the appearance of the ECG in the infarcted zone slightly, in addition to prolonging its duration. Thus, prolongation of epicardial activation delay induced by amitriptyline may result not only from delayed conduction but also from a change in propagation pathways.
Amitriptyline prolonged the ERP in the present study. Prolongation of the ERP is observed with most antiarrhythmic drugs and contributes to their antiarrhythmic effects (Harrison 1985) . However, in the present study, amitriptyline showed an arrhythmogenic action, which may be due to prolongation of activation delay. Moreover, amitriptyline markedly prolonged the ERP in the infarcted zone, but did not greatly prolong the ERP in the normal zone, suggesting that it may cause dispersion of refractoriness. It has been reported that dispersion of refractoriness provides a substrate for ventricular reentry (Gough et al. 1985) .
It has been reported that the effect of amitriptyline in predisposing to norepinephrine-induced dysrhythmias is not related to blockade of norepinephrine uptake in isolated rabbit hearts (Harper and Hughes 1977) . In the present study, we investigated whether the inhibition of norepinephrine reuptake by amitriptyline contributes to epicardial activation delay or arrhythmias by combination with propranolol pretreatment. Propranolol did not affect the epicardial activation delay caused by amitriptyline or the incidence of ventricular arrhythmias induced by PES. These results suggest that the electrophysiological effects of amitriptyline in this model may not contribute to the inhibition of norepinephrine reuptake.
Fluvoxamine did not adversely affect the epicardial activation delay of premature excitations, the ERP, the incidence of arrhythmias induced by PES, or the ECG in the present study. Fluvoxamine is an SSRI which has only a very weak norepinephrine-uptake-inhibiting activity and has no significant affinity for the cholinergic receptor (Claassen et al. 1977; Claassen 1983) . Fluvoxamine can be expected to show different cardiovascular effects from the TCAs because of its different pharmacological action. There is evidence in support of the lower cardiotoxicity of ttuvoxamine. In conscious rabbits, the intravenous infusion of amitriptyline induced severe arrhythmias and ECG disturbances at relatively low doses, while arrhythmias were infrequently seen with ttuvoxamine (Wouters and Deiman 1983) . At sublethal doses, effects on cardiac contractility, as assessed by left ventricular dp/dt, were markedly decreased after amitriptyline, but moderately after fluvoxamine (Wouters and Deiman 1983) . Fluvoxamine did not affect sympathetic cardiovascular regulation in anaesthetized rabbits (Szabo et al. 1992) . The effects of fluvoxamine on the human ECG have been studied on several occasions and reviewed by Roos (1983) . Fluvoxamine had no effects on the ECG except for a slight and clinically unimportant slowing of the HR (Roos 1983) . However, the electrophysiological effects of fluvoxamine on infarcted animal hearts have not yet been reported. Our observations suggest that fluvoxamine has no effect on ventricular conduction. Therefore, fluvoxamine may not have an arrhythmogenic effect such as that of amitriptyline.
From the present results, we can draw the following conclusion. Amitriptyline, at a dose of 3 mg/kg, markedly prolonged epicardial activation delay of premature excitations in a frequency-dependent manner in the infarcted zone. Amitriptyline prolonged the ERP particularly in the infarcted zone and increased the incidence of ventricular arrhythmias induced by PES. The effects of amitriptyline on epicardial activation delay and PES may not contribute to the inhibition of norepinephrine reuptake. In contrast, fluvoxamine has no effects on epicardial activation delay of premature excitations in normal or infarcted myocardium, and has no effects on the ERP or PES. Considering these electrophysiological effects, fluvoxamine may be preferable for depressive patients with myocardial infarction or ischaemic heart disease.
